Compare · ANIK vs BDX
ANIK vs BDX
Side-by-side comparison of Anika Therapeutics Inc. (ANIK) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANIK and BDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.38B, about 249.2x ANIK ($166.0M).
- Over the past year, ANIK is down 15.5% and BDX is down 29.8% - ANIK leads by 14.3 points.
- BDX has been more active in the news (14 items in the past 4 weeks vs 7 for ANIK).
- BDX has more recent analyst coverage (25 ratings vs 11 for ANIK).
- Company
- Anika Therapeutics Inc.
- Becton Dickinson and Company
- Price
- $12.34-19.19%
- $145.31-2.82%
- Market cap
- $166.0M
- $41.38B
- 1M return
- -12.85%
- -6.06%
- 1Y return
- -15.48%
- -29.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 14
- Recent ratings
- 11
- 25
Anika Therapeutics Inc.
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest ANIK
- Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Anika Reports First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by Anika Therapeutics Inc.
- SEC Form DEF 14A filed by Anika Therapeutics Inc.
- Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
- Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
- Telix Strengthens Board with Additional Director Appointments
- Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.
- SEC Form 4 filed by Mcleod Ian
Latest BDX
- Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,244 worth of shares (74 units at $151.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,159 units (SEC Form 4)
- BD to Present at Bank of America Securities Health Care Conference
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD